Berenberg Bank Keeps Their Buy Rating on AstraZeneca (AZN)
In a report released yesterday, from Berenberg Bank maintained a Buy rating on AstraZeneca, with a price target of $110.00. The company’s shares closed yesterday at $95.60.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Currently, the analyst consensus on AstraZeneca is a Strong Buy with an average price target of $106.75, an 11.66% upside from current levels. In a report released on January 21, Morgan Stanley also maintained a Buy rating on the stock with a $104.00 price target.
Based on AstraZeneca’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $15.19 billion and a net profit of $2.53 billion. In comparison, last year the company earned a revenue of $13.57 billion and had a net profit of $1.43 billion
Read More on AZN:
Disclaimer & DisclosureReport an Issue
- AstraZeneca’s AZD3974 Enters Early Human Testing: What Investors Should Watch
- AstraZeneca’s AZD1163 Clears Early Safety Hurdle: What Phase I Completion Means for Investors
- AstraZeneca initiated with a Buy at Citi
- AstraZeneca Sharpens Andexanet Strategy With New Phase I Dosing Study
- AstraZeneca Halts Early Heart Drug Study: What It Means for AZN Investors
